Published in AIDS on July 01, 2003
Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav (2006) 8.11
Integrating HIV prevention and treatment: from slogans to impact. PLoS Med (2005) 6.73
Understanding and addressing AIDS-related stigma: from anthropological theory to clinical practice in Haiti. Am J Public Health (2005) 4.85
Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr (2009) 3.41
Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr (2007) 2.67
Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. PLoS One (2010) 2.05
Antiretroviral treatment roll-out in a resource-constrained setting: capitalizing on nursing resources in Botswana. Bull World Health Organ (2007) 2.02
"That is why I stopped the ART": patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. BMC Public Health (2008) 1.96
Adherence to antiretroviral therapy: merging the clinical and social course of AIDS. PLoS Med (2005) 1.77
The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol (2005) 1.76
Outcomes after virologic failure of first-line ART in South Africa. AIDS (2010) 1.74
Predictors of adherence to antiretroviral therapy in rural Zambia. J Acquir Immune Defic Syndr (2008) 1.73
Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi. PLoS One (2013) 1.70
Determinants of Adherence to Antiretroviral Therapy among HIV-Infected Patients in Africa. AIDS Res Treat (2012) 1.51
Medication adherence and its determinants among patients on concomitant tuberculosis and antiretroviral therapy in South west ethiopia. N Am J Med Sci (2012) 1.47
Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr (2009) 1.45
Antiretroviral treatment adherence and its determinants in Sub-Saharan Africa: a prospective study at Yaounde Central Hospital, Cameroon. AIDS Res Ther (2009) 1.44
Financial barriers to HIV treatment in Yaoundé, Cameroon: first results of a national cross-sectional survey. Bull World Health Organ (2009) 1.42
Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature. Retrovirology (2008) 1.30
Knowledge and adherence to antiretroviral therapy among adult people living with HIV/AIDS treated in the health care centers of the association "Espoir Vie Togo" in Togo, West Africa. BMC Clin Pharmacol (2010) 1.18
Alcohol use and non-adherence to antiretroviral therapy in HIV-infected patients in West Africa. Addiction (2010) 1.17
Livelihood security and adherence to antiretroviral therapy in low and middle income settings: a systematic review. PLoS One (2011) 1.09
Antiretroviral drug resistance and routine therapy, Cameroon. Emerg Infect Dis (2006) 1.08
Factors associated with self-reported adherence to antiretroviral therapy in a Tanzanian setting. AIDS Care (2010) 1.05
Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. BMC Public Health (2010) 1.04
Barriers to better care for people with AIDS in developing countries. BMJ (2004) 1.03
Consistent ART adherence is associated with improved quality of Life, CD4 counts, and reduced hospital costs in central China. AIDS Res Hum Retroviruses (2009) 0.99
Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother (2004) 0.98
Determinants of optimal adherence over time to antiretroviral therapy amongst HIV positive adults in South Africa: a longitudinal study. AIDS Behav (2011) 0.97
Adherence to highly active antiretroviral therapy in a tertiary care hospital in West Bengal, India. Singapore Med J (2014) 0.95
Socioeconomic factors in adherence to HIV therapy in low- and middle-income countries. J Health Popul Nutr (2013) 0.95
Reduced adherence to antiretroviral therapy among HIV-infected Tanzanians seeking cure from the Loliondo healer. J Acquir Immune Defic Syndr (2014) 0.92
Care of patients on anti-retroviral therapy in kumasi metropolis. Ghana Med J (2009) 0.88
Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges. HIV Ther (2009) 0.83
Assessment of the impact of adherence and other predictors during HAART on various CD4 cell responses in resource-limited settings. Patient Prefer Adherence (2012) 0.83
Missed Doses and Missed Appointments: Adherence to ART among Adult Patients in Uganda. ISRN AIDS (2013) 0.80
[Study of factors related to adherence to antiretroviral therapy among patients followed at HIV/AIDS Unit in the District Hospital of Dschang, Cameroon]. Pan Afr Med J (2012) 0.79
NGO-provided free HIV treatment and services in Burkina Faso: scarcity, therapeutic rationality and unfair process. Int J Equity Health (2012) 0.78
Impact of variability in adherence to HIV antiretroviral therapy on the immunovirological response and mortality. BMC Med Res Methodol (2015) 0.78
Determinants of adherence to antiretroviral therapy among HIV-positive adults in sub-Saharan Africa: a systematic review. BMJ Glob Health (2016) 0.78
Free antiretrovirals must not be restricted only to treatment-naive patients. Experience in Uganda suggests that restricting access is not the way forward. PLoS Med (2005) 0.77
[Factors associated with non-adherence of adults infected with HIV on antiretroviral therapy in a referral hospital in Douala]. Pan Afr Med J (2015) 0.75
Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV. Infect Dis Obstet Gynecol (2014) 0.75
Free HIV antiretroviral therapy enhances adherence among individuals on stable treatment: implications for potential shortfalls in free antiretroviral therapy. PLoS One (2013) 0.75
The "free by 5" campaign for universal, free antiretroviral therapy. PLoS Med (2005) 0.75
Antiretroviral drug diversion links social vulnerability to poor medication adherence in substance abusing populations. AIDS Behav (2015) 0.75
Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science (2006) 7.12
Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS (2006) 6.46
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet (2004) 4.81
Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68
Origin of the human malaria parasite Plasmodium falciparum in gorillas. Nature (2010) 4.35
The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS (2002) 4.01
Human immunodeficiency viruses: SIV infection in wild gorillas. Nature (2006) 3.35
Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr (2005) 3.09
Risk to human health from a plethora of simian immunodeficiency viruses in primate bushmeat. Emerg Infect Dis (2002) 2.98
Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis (2011) 2.82
HIV infection and sexually transmitted infections among men who have sex with men in Senegal. AIDS (2005) 2.71
African great apes are natural hosts of multiple related malaria species, including Plasmodium falciparum. Proc Natl Acad Sci U S A (2010) 2.60
Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. Clin Infect Dis (2013) 2.53
Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infect Dis (2013) 2.51
Genetic diversity and phylogeographic clustering of SIVcpzPtt in wild chimpanzees in Cameroon. Virology (2007) 2.01
Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS (2003) 1.94
Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis (2005) 1.73
Women's views on consent, counseling and confidentiality in PMTCT: a mixed-methods study in four African countries. BMC Public Health (2012) 1.69
Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon. Antivir Ther (2013) 1.68
New simian immunodeficiency virus infecting De Brazza's monkeys (Cercopithecus neglectus): evidence for a cercopithecus monkey virus clade. J Virol (2004) 1.68
Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing. J Clin Microbiol (2009) 1.65
Identification of a new simian immunodeficiency virus lineage with a vpu gene present among different cercopithecus monkeys (C. mona, C. cephus, and C. nictitans) from Cameroon. J Virol (2003) 1.61
Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. AIDS (2011) 1.55
Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr (2002) 1.51
Prevalence of intestinal parasites including microsporidia in human immunodeficiency virus-infected adults in Cameroon: a cross-sectional study. Am J Trop Med Hyg (2006) 1.48
Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon. PLoS One (2009) 1.43
Molecular epidemiology of simian immunodeficiency virus infection in wild-living gorillas. J Virol (2009) 1.42
Widespread infection with homologues of human parvoviruses B19, PARV4, and human bocavirus of chimpanzees and gorillas in the wild. J Virol (2010) 1.42
Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antivir Ther (2009) 1.35
Associations between mode of HIV testing and consent, confidentiality, and referral: a comparative analysis in four African countries. PLoS Med (2012) 1.35
Distribution of HIV-1 variants in the Democratic Republic of Congo suggests increase of subtype C in Kinshasa between 1997 and 2002. J Acquir Immune Defic Syndr (2005) 1.34
Simian T-cell leukemia virus (STLV) infection in wild primate populations in Cameroon: evidence for dual STLV type 1 and type 3 infection in agile mangabeys (Cercocebus agilis). J Virol (2004) 1.30
Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. Antivir Ther (2005) 1.30
Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study. AIDS Res Hum Retroviruses (2009) 1.25
Detection and genetic characterization of enteroviruses circulating among wild populations of chimpanzees in Cameroon: relationship with human and simian enteroviruses. J Virol (2011) 1.23
Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping. J Antimicrob Chemother (2010) 1.22
High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo. J Int AIDS Soc (2011) 1.21
CRF06-cpx: a new circulating recombinant form of HIV-1 in West Africa involving subtypes A, G, K, and J. J Acquir Immune Defic Syndr (2002) 1.21
Adherence to antiretroviral treatment in HIV-positive patients in the Cameroon context: promoting the use of medication reminder methods. J Acquir Immune Defic Syndr (2011) 1.21
Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions. Infect Genet Evol (2009) 1.20
Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia. J Clin Microbiol (2013) 1.20
Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. AIDS Res Hum Retroviruses (2008) 1.19
Revisiting long-term adherence to highly active antiretroviral therapy in Senegal using latent class analysis. J Acquir Immune Defic Syndr (2011) 1.19
Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS (2003) 1.15
HIV-1 subtypes and recombinants in the Republic of Congo. Infect Genet Evol (2006) 1.14
Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon. J Acquir Immune Defic Syndr (2008) 1.14
A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients. Trop Med Int Health (2007) 1.13
Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J Acquir Immune Defic Syndr (2004) 1.13
HIV-1 superinfections in a cohort of commercial sex workers in Burkina Faso as assessed by an autologous heteroduplex mobility procedure. AIDS (2004) 1.11
Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings. Expert Opin Drug Saf (2008) 1.10
HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther (2006) 1.09
Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study. J Acquir Immune Defic Syndr (2009) 1.08
Antiretroviral drug resistance and routine therapy, Cameroon. Emerg Infect Dis (2006) 1.08
Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon. J Int AIDS Soc (2013) 1.07
Identification and molecular characterization of new STLV-1 and STLV-3 strains in wild-caught nonhuman primates in Cameroon. Virology (2007) 1.07
Virological failure rates and HIV-1 drug resistance patterns in patients on first-line antiretroviral treatment in semirural and rural Gabon. J Int AIDS Soc (2012) 1.05
Risk of virological failure and drug resistance during first and second-line antiretroviral therapy in a 10-year cohort in Senegal: results from the ANRS 1215 cohort. J Acquir Immune Defic Syndr (2013) 1.05
Factors associated with late antiretroviral therapy initiation in Cameroon: a representative multilevel analysis. J Antimicrob Chemother (2013) 1.05
Molecular tracing of sexual HIV Type 1 transmission in the southwest border of China. AIDS Res Hum Retroviruses (2008) 1.04
HIV testing and care in Burkina Faso, Kenya, Malawi and Uganda: ethics on the ground. BMC Int Health Hum Rights (2013) 1.03
Barriers to better care for people with AIDS in developing countries. BMJ (2004) 1.03
Molecular epidemiological tracing of HIV-1 outbreaks in Hainan island of southern China. AIDS (2009) 1.03
Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J Clin Virol (2006) 1.03
Novel multiplexed HIV/simian immunodeficiency virus antibody detection assay. Emerg Infect Dis (2011) 1.02
Resistance to antiretroviral drugs in treated and drug-naive patients in the Democratic Republic of Congo. J Acquir Immune Defic Syndr (2011) 1.02
Full-length sequence analysis of SIVmus in wild populations of mustached monkeys (Cercopithecus cephus) from Cameroon provides evidence for two co-circulating SIVmus lineages. Virology (2006) 1.02
Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine. AIDS (2007) 1.01
Widely varying SIV prevalence rates in naturally infected primate species from Cameroon. Virology (2005) 1.01
Couples, PMTCT programs and infant feeding decision-making in Ivory Coast. Soc Sci Med (2009) 1.01
Prevalence of HIV and other sexually transmitted infections, and risk behaviours in unregistered sex workers in Dakar, Senegal. AIDS (2003) 1.01
Molecular evidence for the presence of Rickettsia Felis in the feces of wild-living African apes. PLoS One (2013) 1.01
Evidence for continuing cross-species transmission of SIVsmm to humans: characterization of a new HIV-2 lineage in rural Côte d'Ivoire. AIDS (2013) 0.99
High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity. J Clin Microbiol (2011) 0.99
Plasmodium falciparum-like parasites infecting wild apes in southern Cameroon do not represent a recurrent source of human malaria. Proc Natl Acad Sci U S A (2013) 0.98
Prevalence and genetic diversity of simian immunodeficiency virus infection in wild-living red colobus monkeys (Piliocolobus badius badius) from the Taï forest, Côte d'Ivoire SIVwrc in wild-living western red colobus monkeys. Infect Genet Evol (2007) 0.98
Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. FEMS Immunol Med Microbiol (2006) 0.97
Full molecular characterization of a simian immunodeficiency virus, SIVwrcpbt from Temminck's red colobus (Piliocolobus badius temminckii) from Abuko Nature Reserve, The Gambia. Virology (2008) 0.97
Complete genome analysis of one of the earliest SIVcpzPtt strains from Gabon (SIVcpzGAB2). AIDS Res Hum Retroviruses (2004) 0.97
Characterization of a new simian immunodeficiency virus strain in a naturally infected Pan troglodytes troglodytes chimpanzee with AIDS related symptoms. Retrovirology (2011) 0.97
Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients. AIDS Res Hum Retroviruses (2008) 0.96
Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort. BMC Infect Dis (2010) 0.95
Evaluation of four simple/rapid assays and two fourth-generation ELISAs for the identification of HIV infection on a serum panel representing the HIV-1 group M genetic diversity in Cameroon. J Acquir Immune Defic Syndr (2004) 0.93
High genetic diversity of HIV-1 strains in Chad, West Central Africa. J Acquir Immune Defic Syndr (2003) 0.93
Identification of a new circulating recombinant form of HIV type 1, CRF11-cpx, involving subtypes A, G, J, and CRF01-AE, in Central Africa. AIDS Res Hum Retroviruses (2002) 0.92
HIV type 1 diversity and antiretroviral drug resistance mutations in Burundi. AIDS Res Hum Retroviruses (2007) 0.92